These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 16151405)

  • 41. Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies.
    Acierno JP; Braden BC; Klinke S; Goldbaum FA; Cauerhff A
    J Mol Biol; 2007 Nov; 374(1):130-46. PubMed ID: 17916365
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.
    Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D
    J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generation and characterization of a high-affinity chimaeric antibody against hepatitis B surface antigen.
    Bose B; Khanna N; Acharya SK; Sinha S
    Biotechnol Appl Biochem; 2006 Feb; 43(Pt 2):93-101. PubMed ID: 16253117
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parallel kinetic analysis and affinity determination of hundreds of monoclonal antibodies using the ProteOn XPR36.
    Nahshol O; Bronner V; Notcovich A; Rubrecht L; Laune D; Bravman T
    Anal Biochem; 2008 Dec; 383(1):52-60. PubMed ID: 18782554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies.
    Li J; Menzel C; Meier D; Zhang C; Dübel S; Jostock T
    J Immunol Methods; 2007 Jan; 318(1-2):113-24. PubMed ID: 17161420
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Science of evaluating the characteristics, quality and safety of biotechnological products: RDNA-derived products, cell culture technology-derived products, gene therapy products, cellular therapy products, and transgenic animal-derived protein products and cellular products].
    Hayakawa T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1999; (117):1-38. PubMed ID: 10859934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.
    Luk JM; Wong KF
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):482-8. PubMed ID: 16700883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.
    Jakobovits A; Amado RG; Yang X; Roskos L; Schwab G
    Nat Biotechnol; 2007 Oct; 25(10):1134-43. PubMed ID: 17921999
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The therapeutic antibodies market to 2008.
    Pavlou AK; Belsey MJ
    Eur J Pharm Biopharm; 2005 Apr; 59(3):389-96. PubMed ID: 15760719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
    Skaricic D; Traube C; De B; Joh J; Boyer J; Crystal RG; Worgall S
    Virology; 2008 Aug; 378(1):79-85. PubMed ID: 18556039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human monoclonal antibodies from transgenic mice.
    Lonberg N
    Handb Exp Pharmacol; 2008; 181(181):69-97. PubMed ID: 18071942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunoglobulin G specifically binding plant N-glycans with high affinity could be generated in rabbits but not in mice.
    Jin C; Bencúrová M; Borth N; Ferko B; Jensen-Jarolim E; Altmann F; Hantusch B
    Glycobiology; 2006 Apr; 16(4):349-57. PubMed ID: 16373330
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles.
    Zvirbliene A; Samonskyte L; Gedvilaite A; Voronkova T; Ulrich R; Sasnauskas K
    J Immunol Methods; 2006 Apr; 311(1-2):57-70. PubMed ID: 16516908
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody conjugates and therapeutic strategies.
    McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
    Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transgenic mice as a source of fully human antibodies for the treatment of cancer.
    Davis CG; Gallo ML; Corvalan JR
    Cancer Metastasis Rev; 1999; 18(4):421-5. PubMed ID: 10855785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Foundation Review: Transgenic animals and their impact on the drug discovery industry.
    Dunn DA; Pinkert CA; Kooyman DL
    Drug Discov Today; 2005 Jun; 10(11):757-67. PubMed ID: 15922934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
    Qin W; Feng J; Li Y; Lin Z; Shen B
    Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Flexibility--the guiding principle for antibody manufacturing.
    Carson KL
    Nat Biotechnol; 2005 Sep; 23(9):1054-8. PubMed ID: 16151390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.
    Figini M; Martin F; Ferri R; Luison E; Ripamonti E; Zacchetti A; Mortarino M; Di Cioccio V; Maurizi G; Allegretti M; Canevari S
    Cancer Immunol Immunother; 2009 Apr; 58(4):531-46. PubMed ID: 18704410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.